Royalty Pharma plc reports developments tied to its biopharmaceutical royalty portfolio and life-sciences funding model. The company acquires existing royalties from medicine innovators and enters direct funding arrangements, including co-funding for late-stage clinical trials and product launches, in exchange for future royalties.
Recurring news covers Portfolio Receipts, Royalty Receipts, operating cash flow, guidance, dividends, royalty transactions, and updates from commercial products and development-stage candidates. Company announcements also address R&D funding collaborations, portfolio clinical and regulatory developments, leadership additions in partnering and technology, investor conference appearances, and scientific initiatives such as the Royalty Pharma Translational Prize.
Royalty Pharma (Nasdaq: RPRX) appointed Lucas Glass as Head of Artificial Intelligence, effective April 2026.
The company said Glass will lead development and implementation of AI capabilities to support royalty evaluation, intelligent automation, advanced analytics and AI-driven decision support, drawing on more than a decade of life‑sciences AI and data experience and prior leadership at IQVIA.
Royalty Pharma (Nasdaq: RPRX) announced expansion of its leadership team, naming Greg Butz as Executive Vice President, Partnering & Investments, effective June 2026. The company also appointed Chris Hite as Chairman, Partnering & Investments and referenced Ken Sun's earlier addition as Head of Asia.
The hires aim to strengthen global origination and execution of royalty transactions, leveraging Butz's two decades of healthcare investment banking experience and Hite's relationship network.
Royalty Pharma (Nasdaq: RPRX) appointed Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Based in Hong Kong, he will lead the company’s royalty business across Asia and expand Royalty Pharma’s global platform.
The appointment follows significant regional deal flow: out‑licensing of Chinese medicines topped $130 billion in 2025, up from about $14 billion in 2021, creating a growing market opportunity for royalty‑based funding.
Royalty Pharma (Nasdaq: RPRX) agreed to provide $250 million to Zymeworks (Nasdaq: ZYME) via a non‑recourse royalty‑backed note secured by 30% of worldwide tiered royalties on Ziihera until repayment.
Repayment ends when Royalty Pharma receives 1.65x the note by Dec 31, 2033, or 1.925x thereafter; Zymeworks retains 70% royalties and all milestone payments up to $1.5 billion potential remaining. Proceeds fund share repurchases, potential acquisitions, and cash runway beyond 2028.
Royalty Pharma (Nasdaq: RPRX) will participate in a fireside chat at TD Cowen’s 46th Annual Health Care Conference on March 3, 2026 at 1:10 p.m. ET. According to the company, the session will be webcast and archived for at least thirty days.
Investors can access the live webcast and archived replay via the company’s Events page.
Royalty Pharma (Nasdaq: RPRX) reported Q4 2025 Portfolio Receipts of $874 million and full‑year 2025 Portfolio Receipts of $3,254 million, growth of 18% Q4 and 16% FY. Net cash provided by operations was $827 million in Q4 and $2,490 million for FY 2025.
The company deployed $2.6 billion on royalty transactions in 2025, repurchased 37 million Class A shares for $1.2 billion, and raised the quarterly dividend 7% to $0.235 per share. Full‑year 2026 Portfolio Receipts guidance is $3,275M–$3,425M.
Royalty Pharma (Nasdaq: RPRX) will report its fourth quarter and full year 2025 financial results on Wednesday, February 11, 2026 before U.S. markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Investors can obtain conference call details and view the live webcast via the company's Investors page, and a replay will be archived on the site for at least 30 days.
Royalty Pharma (Nasdaq: RPRX) provided a business update and will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026.
Key highlights: the announced royalty funding market reached a record $10 billion in 2025; Royalty Pharma announced $4.7 billion of transactions in 2025 (capital deployment of $2.6 billion), representing ~40% market share. The company expects to meet 2025 Portfolio Receipts guidance of $3,200–$3,250 million (14%–16% growth) and reported trailing twelve‑month ROIC 15.7% and ROIE 22.9%. Multiple 2026 milestones are anticipated, including pivotal readouts for daraxonrasib, litifilimab and pelacarsen, and several potential approvals; late‑stage pipeline peak sales potential exceeds $43 billion, which could translate to >$2.1 billion annually in new royalties.
Royalty Pharma (Nasdaq: RPRX) agreed to provide up to $500 million to accelerate Teva's anti‑IL‑15 antibody, TEV‑'408, including $75 million of R&D co‑funding to support a Phase 2b vitiligo study targeted to start in 2026 and a Royalty Pharma option to provide an additional $425 million to co‑fund a Phase 3 program. TEV‑'408 is currently in Phase 1b for vitiligo and Phase 2a for celiac disease, and Teva expects to share trial results during 2026.
If approved and launched, Teva will pay a milestone to Royalty Pharma and a royalty on worldwide net sales of TEV‑'408.
Royalty Pharma (Nasdaq: RPRX) announced a first-quarter 2026 dividend of $0.235 per Class A ordinary share, representing a 6.8% increase versus the prior quarter. The dividend will be paid on March 10, 2026 to shareholders of record at the close of business on February 20, 2026.